Key points are not available for this paper at this time.
After 3 years, D-Vd maintained significant benefits in patients with relapsed or refractory multiple myeloma with a consistent safety profile. D-Vd provided the greatest benefit at first relapse and increased MRD-negativity rates.
Building similarity graph...
Analyzing shared references across papers
Loading...
María‐Victoria Mateos
Pieter Sonneveld
Vânia Hungria
Clinical Lymphoma Myeloma & Leukemia
Emory University
The University of Sydney
Monash University
Building similarity graph...
Analyzing shared references across papers
Loading...
Mateos et al. (Wed,) studied this question.
www.synapsesocial.com/papers/69da8d11a6045d71bfa3d05a — DOI: https://doi.org/10.1016/j.clml.2019.09.623